Clinical Trials Logo

Vestibular Schwannomas clinical trials

View clinical trials related to Vestibular Schwannomas.

Filter by:
  • None
  • Page 1

NCT ID: NCT02129647 Completed - Clinical trials for Neurofibromatosis Type 2

Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas

Start date: April 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if the study drug, AXITINIB, has any effect on tumors found in patients with Neurofibromatosis Type 2 (NF2).

NCT ID: NCT01880749 Completed - Clinical trials for Neurofibromatosis Type 2

Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas

Start date: June 2013
Phase: Early Phase 1
Study type: Interventional

The primary objective is to estimate the proportions of vestibular schwannomas (VS) and meningiomas after 10 days of exposure to the study drug RAD001 at a dose of 10 mg daily, as determined by immunohistochemistry. This is a "phase 0" PK (pharmacokinetic) and PD (pharmacodynamic) study of RAD001 in patients with Neurofibromatosis Type 2-related and sporadic VS and meningiomas. Enrolled patients will take RAD001 prior to a scheduled VS or meningioma surgery, and blood and tissue samples will be obtained for further analysis.